Overview

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Status:
Recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Phase:

Phase 2

Details

Lead Sponsor:

Aptinyx

Collaborators:

CogState Ltd.
Worldwide Clinical Trials